Abiraterone acetate

Drug #2272

Arbitarone acetate is a hormone antagonist which is an androgen biosynthesis inhibitor when converted to abiraterone in vivo. it is indicated in prostatic cancer.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 391.55 · Solubility in Water: 34 · Solubility in Alcohol: 12 · Non-proprietary name: Abiraterone acetate.

Molecular structure of Abiraterone acetate

Pharmacokinetics

None recorded.

Indications

Abiraterone acetate is primarily indicated in conditions like Prostate cancer.

Contraindications

Abiraterone acetate is contraindicated in conditions like Hypersensitivity, Pregnancy.

Dosage

Abiraterone acetate's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
1000 mg	1000 mg	Every 1h	PO	Must not be taken with food. Taken with 10 mg prednisolone.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

4 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Abiraterone acetate in overdosage may give rise to further complications which include Hepatotoxicity .

Abiraterone acetate produces potentially life-threatening effects which include Angina pectoris, Cardiac failure, CHF , Atrial fibrillation, arrythmia, left ventricular dysfunction, ejection fraction decreased. Careful monitoring is needed with proper medical management.

Abiraterone acetate is known to cause more or less tolerable side effects which are usually transient. These include adrenal insufficiency, Elevated hepatic transaminases, Hypertension , Hypokalemia , Hypotension , Peripheral edema, UTI .

Warnings / Precautions

Use with caution in patients with a history of cardiovascular disease. Before treatment hypertension must be controlled and hypokalemia must be corrected. Use with caution in patients with increase blood pressure or fluid retention, severe or unstable angina pectoris, recent myocardial infarction or ventricular arrythmia and severe renal impairment. Discontinue in severe hepatotoxicity. Decrease bone density may occur so use of glucocorticoid is advised. Patient with lactose intolerance should not take this drug. It is not for use in women with a child bearing potential.

Available Brands

None recorded.